1. Home
  2. LPCN vs ZBAI Comparison

LPCN vs ZBAI Comparison

Compare LPCN & ZBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPCN
  • ZBAI
  • Stock Information
  • Founded
  • LPCN 1997
  • ZBAI 2015
  • Country
  • LPCN United States
  • ZBAI United States
  • Employees
  • LPCN N/A
  • ZBAI N/A
  • Industry
  • LPCN Biotechnology: Pharmaceutical Preparations
  • ZBAI Professional Services
  • Sector
  • LPCN Health Care
  • ZBAI Consumer Discretionary
  • Exchange
  • LPCN Nasdaq
  • ZBAI Nasdaq
  • Market Cap
  • LPCN 16.1M
  • ZBAI 17.3M
  • IPO Year
  • LPCN N/A
  • ZBAI N/A
  • Fundamental
  • Price
  • LPCN $3.16
  • ZBAI $1.02
  • Analyst Decision
  • LPCN Strong Buy
  • ZBAI
  • Analyst Count
  • LPCN 1
  • ZBAI 0
  • Target Price
  • LPCN $10.00
  • ZBAI N/A
  • AVG Volume (30 Days)
  • LPCN 22.1K
  • ZBAI 135.6K
  • Earning Date
  • LPCN 05-08-2025
  • ZBAI 03-13-2025
  • Dividend Yield
  • LPCN N/A
  • ZBAI N/A
  • EPS Growth
  • LPCN N/A
  • ZBAI N/A
  • EPS
  • LPCN N/A
  • ZBAI N/A
  • Revenue
  • LPCN $3,674,834.00
  • ZBAI $670,000.00
  • Revenue This Year
  • LPCN N/A
  • ZBAI N/A
  • Revenue Next Year
  • LPCN N/A
  • ZBAI N/A
  • P/E Ratio
  • LPCN N/A
  • ZBAI N/A
  • Revenue Growth
  • LPCN N/A
  • ZBAI 67.50
  • 52 Week Low
  • LPCN $2.75
  • ZBAI $0.58
  • 52 Week High
  • LPCN $11.79
  • ZBAI $2.50
  • Technical
  • Relative Strength Index (RSI)
  • LPCN 48.60
  • ZBAI N/A
  • Support Level
  • LPCN $2.68
  • ZBAI N/A
  • Resistance Level
  • LPCN $3.46
  • ZBAI N/A
  • Average True Range (ATR)
  • LPCN 0.33
  • ZBAI 0.00
  • MACD
  • LPCN -0.02
  • ZBAI 0.00
  • Stochastic Oscillator
  • LPCN 51.97
  • ZBAI 0.00

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

About ZBAI ATIF Holdings Limited Ordinary Shares

ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.

Share on Social Networks: